Slides
Page 1
BRILLIANCE : A Phase 1/2 Single Ascending Dose Study of EDIT - 101 , an in vivo CRISPR Gene Editing Therapy in CEP290 - Related Retinal Degeneration September 29 , 2021 editas MEDICINE
Loading workspace
BRILLIANCE : A Phase 1/2 Single Ascending Dose Study of EDIT - 101 , an in vivo CRISPR Gene Editing Therapy in CEP290 - Related Retinal Degeneration September 29 , 2021 editas MEDICINE
Your watchlist and earnings event details are available after you sign in.